{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:55:12Z","timestamp":1788317712698,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Inner Mongolia","doi-asserted-by":"publisher","award":["2013MS1157"],"award-info":[{"award-number":["2013MS1157"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003564","name":"Inner Mongolia Autonomous Region Health and Family Planning health research projects","doi-asserted-by":"publisher","award":["201302059"],"award-info":[{"award-number":["201302059"]}],"id":[{"id":"10.13039\/501100003564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.leukres.2014.06.019","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T20:03:28Z","timestamp":1405454608000},"page":"1177-1183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Interferon \u03b1-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation"],"prefix":"10.1016","volume":"38","author":[{"given":"Bin-Tao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Chun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.06.019_bib0005","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2014.06.019_bib0015","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.21946","article-title":"Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.06.019_bib0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.leukres.2014.06.019_bib0030","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.06.019_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.06.019_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/ehm.12.69","article-title":"Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"6","author":"Silver","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.leukres.2014.06.019_bib0045","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00432-013-1570-6","article-title":"How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study","volume":"140","author":"Huang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.leukres.2014.06.019_bib0055","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet (ELN) consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0060","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.06.019_bib0065","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0070","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0075","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.06.019_bib0080","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2014.06.019_bib0085","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.06.019_bib0090","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.06.019_bib0095","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","article-title":"A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs","volume":"89","author":"Crisa","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2014.06.019_bib0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.blre.2012.06.002","article-title":"Front-line therapy in polycythemia vera and essential thrombocythemia","volume":"26","author":"Barbui","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.leukres.2014.06.019_bib0105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T08:54:28Z","timestamp":1598086468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0145212614001982"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.06.019","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon \u03b1-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}